Interestingly, a reduction of CD28+CD57-CD8+ and an increase of CD28-CD57+CD8+ T cells has been observed in patients with advanced lung cancer, accounting for a reduced proliferative capacity and dysfunctional antitumor activity [14,24]. This evidence concerns the gene B3GAT1 and lung cancer.